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Purpose or Objective: The intent of this pooled analysis as 
part of the German Society for Radiation Oncology (DEGRO) 
stereotactic body radiotherapy (SBRT) initiative was to 
analyse the pattern of care of SBRT for liver metastases in 
Germany and to derive factors influencing local control and 
overall survival in a large patient cohort. 
 
Material and Methods: From 17 German and Swiss 
radiotherapy centers, data on all patients treated for liver 
metastases with SBRT since its introduction in 1997 was 
collected and entered into a centralised database as an 
effort of the SBRT task group of the DEGRO. In addition to 
patient and tumor characteristics, data on immobilization, 
image guidance and motion management as well as dose 
prescription and fractionation was gathered. Besides dose 
response and survival statistics, time trends of the 
aforementioned variables were investigated. 
 
Results: In total, 442 patients with 586 liver metastases 
(median 1 lesion/patient; range 1-4) have been collected 
from 1997 until 2014. Predominant histologies were 
colorectal cancer (n=213), lung cancer (n=26) and breast 
cancer (n=57). All centers employed a SBRT-specific setup 
(including abdominal compression in 41%). Initially, 
stereotactic coordinates and CT simulation was used for 
treatment set-up (55%), but eventually replaced by CBCT 
guidance (28%) or more recently robotic tracking (17%). High 
variance in fraction (fx) number (median 1 fx; range 1-13) 
and dose per fraction (median: 18.5 Gy; range 3-37.5 Gy) was 
observed, although median BED remained consistently high 
after an initial learning curve. Median follow-up time was 13 
months; median overall survival after SBRT was 24 months. 1 
and 2 year local control rate of treated lesions was 77% and 
64%; local control increased to 83% and 70%, respectively, if 
maximum isocenter biological equivalent dose (BED) was 
greater than 120 Gy EQD2Gy versus below that dose. 
 
Conclusion: After a learning curve with regards to total 
cumulative doses, consistent biologically effective doses 
were employed, although with a significant variation in 
number of fraction, single fraction dose and prescription 
isodose. A clear dose response was observed with high local 
control after 1 and 2 years with higher BED. Nevertheless, 
local control is still inferior compared to lung metastases 
with a similar distribution of histologies. Therefore, further 
analysis needs to investigate the influence of image guidance 
and motion management as well as radiation sensitivity on 
local tumor control. 
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Purpose or Objective: To define maximum tolerated dose 
(MTD) of stereotactic treatment (SBRT) performed in 
different clinical settings. 
 
Material and Methods: This analysis was based on a dose-
escalation (Phase I) trial. Patients were enrolled in seven 
different arms depending on treatment site and previous 
treatment: 1) intraparenchymal lung tumors; 2) lung tumors 
near to chest wall or to mediastinum; 3) extra pulmonary 
tumors; 4) re-irradiation after radiotherapy (< 60 Gy); 5) re-
irradiation after radiotherapy (> 60 Gy) or re-irradiation of 
pelvic and pancreatic tumors; 6) boost after a dose < 50Gy; 
7) boost after a dose ≥ 50Gy. SBRT was delivered in 5  
fractions. The dose was prescribed at isocenter with a 3D 
static technique using 4-5 non-coplanar beams or with VMAT 
technique. PTV was defined as the GTV + 5-15 mm. 
Considering study arms, the first group of patients received 
20 Gy, while other cohorts of patients received doses up to 
50 Gy. Grade 3 acute and late toxicities were considered as 
dose limiting toxicity (DLT). If 2/6 or 4/12 DLT were recorded 
in one cohort, that dose was considered as MTD. 
 
 
 
Results: 213 patients were enrolled (M/F: 125/88), median 
age was 69 years (35-90) and 281 lesions were treated (102 
primary tumors or local recurrences, 96 nodal and 83 distant 
metastases); they were mainly lung cancer (31%), 
gynaecologic cancer (24%), gastrointestinal neoplasms (22%), 
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urologic tumour (12%), in the following sites: 150 in neck or 
chest, 70 in abdomen and 61 in pelvis. With a median follow-
up of 17 months (3-131) the overall response rate was 82% 
(Complete Response: 58%; Partial Response: 24%), with only 
3% of patients developing disease progression. DLT was 
recorded only in two patients, both treated with 50 Gy. Two-
year and 4-year local control were 71% and 62%, respectively. 
Two-year and 4-year metastases free survival were 46% and 
39%, respectively. 
 
Conclusion: SBRT in five fractions up to a dose of 50 Gy is 
well tolerated in different clinical settings. 
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Purpose or Objective: Oligometastatic prostate cancer is a 
state of limited metastatic disease (≤ 3 sites) that may be 
amenable to aggressive local therapy to achieve long term 
survival. The use of SBRT in this clinical setting has been 
reported to confer local control rate in excess of 90%, and 
encouraging progression free survival rate with no significant 
treatment –related toxicities1-4. One of the goals with this 
approach is to delay initiation of palliative systemic 
treatment, which can potentially impact negatively on 
quality of life. This study evaluated the outcomes of SBRT in 
our cohort.  
 
Material and Methods: Forty five patients diagnosed with 
oligometastatic prostate cancer (defined as a rising PSA and 
positive CT/PET choline scan) after definitive local therapy 
were treated with 1-2 courses of SBRT between July 2011 and 
July 2015. Over 90% of metastases were situated in lymph 
nodes or bone. Median dose was 30 Gy in 3 fractions, 
prescribed to the highest isodose covering the PTV. 
Retrospective data collection and analysis were performed 
for these patients. Kaplan-Meier was utilised to estimate 
progression free survival and overall survival and time to 
initiation of systemic treatment. Nineteen of the 35 patients 
with castration sensitive disease were treated with SBRT 
alone for their oligometastatic disease, 16 patients received 
SBRT and Androgen Deprivation Therapy (ADT) with median 
duration of 5 months. 10 patients who were castration 
resistant at the diagnosis of oligometastases were treated 
with SBRT with ongoing systemic treatment.  
 
Results: The median follow-up was 29 months (range 6-60 
months). Local control rate of lesions following SBRT 
treatment was 90%, overall progression free survival (PFS) 
was 38%, overall survival (OS) of 89% at 29 months. A 
reduction of pre-treatment PSA value of 48% and 75%, 
respectively was seen in castration sensitive patients who 
received SBRT alone and SBRT with ADT, and a 25% PSA 
reduction in castration resistant patients treated with SBRT 
and ADT. Median time to clinical progression was longer in 
castration sensitive patients treated with SBRT and ADT 
compared to SBRT alone (13 months vs 25 months). The 
median ADT-free survival for castration sensitive patients was 
16 months. Median time to initiation of next line therapy in 
castration resistant patients following SBRT treatment was 6 
months. No grade 3 or 4 treatment related toxicities 
reported. 
 
Conclusion: SBRT can provide a substantial delay to the next 
initiation of systemic therapy in castration sensitive patients 
whilst for castration resistant patients, there is a modest 
prolongation before initiation of subsequent therapy. Phase 
III data is lacking but will shortly be addressed in the SABR-
COMET and CORE trials.  
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Purpose or Objective: Radiobiological findings suggest an 
improvement in the therapeutic ratio for prostate cancer 
(PCa) treated with hypofractionation, compared with 
conventional fractionation. On this basis, in 2012 we 
activated a prospective study on extreme hypofractionated 
image-guided intensity modulated radiation therapy (IG-
IMRT) in organ-confined PCa. The aim of this study is the 
assessment of the feasibility of the proposed protocol – Give 
me five, in terms of acute and late toxicity and biochemical 
efficacy. 
 
Material and Methods: The study was performed within the 
Institutional Ethics Committee notification regarding 
hypofractionated IGRT for PCa. Inclusion criteria were: low 
to intermediate-risk (according to NCCN risk categories) 
histologically confirmed PCa; personalized indication for 
high-risk patients; prostate volume <100cm3; N0 and cM0; 
age >18 years; specific informed consent. In 10% of patients, 
multiparametric MRI was used for an improved definition of 
the patient anatomy, in addition to CT imaging. The nominal 
prescription dose was 32.5 or 35 Gy scheduled in 5 fractions 
on alternate days (therefore the name of protocol, “Give me 
five”), namely 6.5-7 Gy/fraction respectively, corresponding 
to a normalized total dose delivered at 2-Gy/fraction of 74.3 
or 85 Gy, respectively, estimating an α/β ratio of 1.5 Gy. 
Dose delivery was performed with VERO®-BrainLab-Mitsubishi 
or RapidArc®-Varian. No fiducial markers were implanted and 
set-up verification was performed daily by means of CBCT 
imaging. Toxicity was evaluated according RTOG/EORTC 
scales. The study was founded by Associazione Italiana per la 
Ricerca sul Cancro - AIRC, grant no. 13218. 
 
Results: Between April 2012 and May 2015, 166 patients were 
eligible. All patients completed the treatment. Median 
follow-up was 12.5 months (range 6-32.7 months). Fifty-
eitght, 83, 24 and 1 patients out of 166 were at low, 
intermediate, high and unknown risk, respectively. Median 
age was 74.3 years, median Gleason score was 6. Considering 
acute toxicity, 89.8%, 7.8%, 2.4% of patients had gastro-
intestinal G0, G1, G2 toxicity, respectively; 54.2%, 35.5%, 
9.6%, 0.6% of patients had genito-urinary G0, G1, G2, G4 
toxicity, respectively. Late toxicity and outcome were 
assessed in 129 patients (6 months minimum follow-up). 
Considering late toxicity, 3.1% and 0.8% of patients had 
gastro-intestinal G1 and G2 toxicity; 12.4%, 6.2% and 0.8% of 
patients had genito-urinary G1, G2, G3 toxicity, respectively. 
Clinical and biochemical progression prostate disease was 
observed in 2/129 of patients; currently, no evidence of 
prostate disease in 127/129 patients. 
